中外制药公布2026年二季度业绩，收入和核心利润同比增长但属排期内财报披露

Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
Jul 24, 2026
Corporate
Chugai Announces 2026 2nd Quarter Results
TOKYO, July 24, 2026 --
Chugai Pharmaceutical Co., Ltd.
(TOKYO: 4519) announced its financial results for the second quarter of fiscal year 2026.
Core revenue of ¥663.3 billion (+14.7%), core operating profit of ¥329.1 billion (+21.0%), and core net income of ¥238.4 billion (+23.2%) were achieved (all changes year-on-year)
Strong growth in domestic and overseas sales, combined with a significant increase in other revenue driven by one-time income, and royalty income related to Hemlibra
®
and NEMLUVIO
, resulted in increased revenue and profit year-on-year
Achieved eight regulatory filings in Japan during the first half of the year, progressing steadily toward achieving the highest number of filings ever planned
R&D activities progressed steadily across both early- and late-stage development, including Chugai-originated projects
For NXT007, which is expected to become a next-generation growth driver, two Phase III studies were initiated
For AQUA07, the third macrocyclic peptide project, entry into the clinical stage was achieved, with dosing in a Phase I study in
ALK
-positive non-small cell lung cancer expected to start shortly
For Enspryng
, developed using Chugai’s proprietary antibody engineering technologies, the U.S. FDA accepted the regulatory application for thyroid eye disease (TED) and granted Priority Review designation
Regarding products out-licensed to third parties, global market penetration of Chugai-originated new products advanced
Export sales and royalty income from NEMLUVIO (nemolizumab), a humanized anti-human IL-31 receptor A monoclonal antibody out-licensed to Galderma, drove revenue growth
As for Foundayo™ (orforglipron), an oral GLP-1 receptor agonist out-licensed to Eli Lilly, prescriptions were driven in the U.S. primarily by GLP-1 naïve patients, and the oral anti-obesity drug market is expanding. Chugai commenced recognition of royalty income from the product in the second quarter
Refer to the information below for details on the financial results:
Quarterly Reports / Finance Reports
https://www.chugai-pharm.co.jp/english/ir/reports_downloads/tanshin.html
Presentation Materials
In addition to Chugai’s business and financial performance, these materials provide updates on our research and development pipeline. Videos and transcripts (including Q&A) will be made available at a later date.
https://www.chugai-pharm.co.jp/english/media/conference.html
[2026 Second Quarter Results]
Core results (Billion JPY)
2026
Jan-Jun
2025
% change
Revenue
663.3
578.5
+14.7%
Domestic sales
237.9
223.3
+6.5%
Overseas sales
328.6
288.1
+14.1%
Other revenue
96.8
67.0
+44.5%
Operating profit
329.1
272.0
+21.0%
Net income
238.4
193.5
+23.2%
[PDF 142KB]
Contact:
For Media
Media Relations Group, Corporate Communications Dept.,
Naoki Kouzai
Tel: +81-3-3273-0881
E-mail:
pr@chugai-pharm.co.jp
For Investors
Investor Relations Group, Corporate Communications Dept.,
Takayuki Sakurai
Tel: +81-3-3273-0554
ir@chugai-pharm.co.jp
Back